Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis,...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA, overpriced on P/FC.
Target Price
The average target price of FYB.DE is 40 and suggests 73% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell